However, optimal implementation of EGFR inhibitors as radiosensitizers depends, in part, on a better understanding of the mechanisms of radiosensitization. Preclinical studies provide important ...

Novel treatments to counteract primary resistance to anti-EGFR therapy will continue to be explored. The emergent mechanisms of resistance to anti-EGFR targeting in KRASwild-type tumors will be ...

The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR ...

The combination of amivantamab and lazertinib shows lower EGFR and MET resistance, offering an advantage over osimertinib alone. Personalized treatment strategies are essential, considering resistance ...

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected ...

31, 2024 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies ... for adult patients ...